Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study

Peter J. Weiden, MD; Alan Breier, MD; Sarah Kavanagh, MPH; Andrew C. Miller, PhD; Stephen K. Brannan, MD; Steven M. Paul, MD

J Clin Psychiatry 2022;83(3):21m14316

ABSTRACT

Objective: To evaluate Positive and Negative Syndrome Scale (PANSS) categorical response rates, time course of response, and symptom subdomains of response with the combination oral agent KarXT (xanomeline–trospium) in the treatment of schizophrenia.

Methods: Post hoc analysis was conducted for EMERGENT-1 (NCT03697252), a 5-week, inpatient, placebo-controlled, phase 2 study of acute psychosis in patients who met DSM-5 criteria for schizophrenia. The EMERGENT-1 study was conducted between September 2018 and August 2019. Categorical thresholds of response used were PANSS total score reductions of ≥ 20%, ≥ 30%, ≥ 40%, and ≥ 50% between baseline and study end. Number needed to treat (NNT) for each categorical threshold was calculated. The proportion of KarXT- and placebo-treated patients achieving each response threshold at weeks 2, 4, and 5 was assessed. Marder 5-factor analysis of PANSS assessed response with KarXT across symptom domains.

Results: A total of 83 patients in the KarXT group and 87 patients in the placebo group were included in the modified intent-to-treat analysis. Response rates with KarXT ranged from 59.0% for a ≥ 20% threshold to 15.7% for a ≥ 50% threshold. All response rates with KarXT were significantly higher than in the placebo arm (P < .05), with NNTs ranging from 3 (≥ 20% improvement) to 11 (≥ 50% improvement). KarXT was associated with a significantly higher response rate relative to placebo as early as 2 weeks for ≥ 20% (P = .0001) and ≥ 30% (P = .0022) thresholds and at 4 weeks for the ≥ 40% (P = .0049) and ≥ 50% (P = .0041) thresholds. Each of the Marder 5 factors showed significant differences favoring KarXT over placebo (P < .05) by 2 weeks and continuing through week 5 (endpoint Cohen d effect sizes, 0.48−0.66).

Conclusions: KarXT provided clinically meaningful responder rates on PANSS total score compared with placebo at each response threshold, providing further support of the successful primary and secondary endpoints. Response was demonstrated as early as 2 weeks relative to placebo. KarXT demonstrated improvements vs placebo in all 5 factors (positive symptoms, negative symptoms, disorganized thought, uncontrolled hostility, and anxiety/depression).

Trial Registration: ClinicalTrials.gov identifier: NCT03697252

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Download Free PDF

References (28)

McCutcheon RA, Pillinger T, Mizuno Y, et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry. 2021;26(4):1310–1320. PubMed CrossRef
McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia: an overview. JAMA Psychiatry. 2020;77(2):201–210. PubMed CrossRef
Bodick NC, Offen WW, Shannon HE, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 4):S16–S22. PubMed
Andersen MB, Fink-Jensen A, Peacock L, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28(6):1168–1175. PubMed CrossRef
McKinzie D, Fischler K, Meyer T, et al. Xanomeline’s activity in rodent models of psychosis: role of central muscarinic receptors and augmentation by risperidone and aripiprazole. Presented at: American Society for Clinical Pathology Annual Meeting. Virtual; October 27–29, 2021.
Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–1039. PubMed CrossRef
Felder CC, Porter AC, Skillman TL, et al. Elucidating the role of muscarinic receptors in psychosis. Life Sci. 2001;68(22–23):2605–2613. PubMed CrossRef
Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010;64(9):1294–1300. PubMed CrossRef
Miller AC, Paul SM, Breier A. Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects. Presented at: American Society for Clinical Pathology Annual Meeting; May 28–31, 2019; Scottsdale, AZ.
Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726. PubMed CrossRef
Staskin D, Sand P, Zinner N, et al; Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007;178(3 Pt 1):978–983, discussion 983–984. PubMed CrossRef
Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111–123. PubMed CrossRef
Citrome L, Du Y, Weiden PJ. Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm. Neuropsychiatr Dis Treat. 2019;15:2639–2646. PubMed CrossRef
Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. PubMed CrossRef
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. American Psychiatric Association; 2013.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218–222.
Correll CU, Kishimoto T, Nielsen J, et al. Quantifying clinical relevance in the treatment of schizophrenia. Clin Ther. 2011;33(12):B16–B39. PubMed CrossRef
Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538–546. PubMed CrossRef
Obermeier M, Schennach-Wolff R, Meyer S, et al. Is the PANSS used correctly? a systematic review. BMC Psychiatry. 2011;11(1):113. PubMed CrossRef
Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. Schizophr Bull. 2010;36(3):461–462. PubMed CrossRef
Brannan SK, Breier A, Weiden PJ, et al. The M1/M4 agonist xanomeline in combination with trospium is effective for acute treatment of schizophrenia: PANSS responder and PANSS 5-factor analyses of a phase 2 placebo-controlled inpatient trial. Presented at: Schizophrenia International Research Society Virtual Congress; April 17–21, 2021.
Wallwork RS, Fortgang R, Hashimoto R, et al. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012;137(1-3):246–250. PubMed CrossRef
Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14(3):229–234. PubMed CrossRef
Citrome L, Risinger R, Cutler AJ, et al. Effect of aripiprazole lauroxil in patients with acute schizophrenia as assessed by the Positive and Negative Syndrome Scale: supportive analyses from a Phase 3 study. CNS Spectr. 2018;23(4):284–290. PubMed CrossRef
Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011;131(1–3):75–81. PubMed CrossRef
Ismail Z, Peters-Strickland T, Miguelez M, et al. Aripiprazole once-monthly in the treatment of acute psychotic episodes in schizophrenia: post hoc analysis of Positive and Negative Syndrome Scale Marder factor scores. J Clin Psychopharmacol. 2017;37(3):347–350. PubMed CrossRef
Carpenter WT Jr, Heinrichs DW, Alphs LD. Treatment of negative symptoms. Schizophr Bull. 1985;11(3):440–452. PubMed CrossRef